About Medoxy
Understand the scope of Medoxy's public product information and how qualified trade requests are handled.
Medoxy Healthcare
Medoxy Healthcare Pvt Ltd operates an inquiry-led pharmaceutical trading website. Its current public catalogue is focused on gastroenterology and is intended for distributors, healthcare organizations, and other qualified business contacts.
Each catalogue entry identifies the listed composition, dosage form, pack information, and a direct inquiry route. These pages support initial product discovery; they are not prescribing resources, authorization records, or substitutes for controlled product documents.
A qualified inquiry can identify the product, intended market, requested records, and business purpose. Medoxy can then confirm what information is applicable and available for that request.
Product details should be checked against current packaging, manufacturer or vendor records, and market-specific requirements before a commercial or clinical decision is made.
The website avoids presenting general quality language as proof of a product, facility, licence, or certification. Product-specific evidence should be requested and reviewed in its proper scope.
Medoxy's public information is written for business discovery. Questions about diagnosis, treatment, dosing, contraindications, or patient use belong with a qualified healthcare professional and the applicable approved product information.
Trade Expertise
Medoxy Healthcare Pvt Ltd is a B2B pharmaceutical trading company based in Gurgaon, Haryana, India, focused on a gastroenterology product catalogue for distributors, stockists, hospitals, institutions, and other qualified healthcare businesses. The product catalogue lists brand names, compositions, dosage forms, and pack sizes across categories such as proton pump inhibitor combinations, antispasmodics, ursodeoxycholic acid, rifaximin, probiotics, antacid and alginate suspensions, and nutritional supplements.
Catalogue entries include Benzispa SR (Mebeverine Hydrochloride Sustained Release), Benzispa Plus (Mebeverine + Chlordiazepoxide), Esomizole-D (Esomeprazole (EC) + Domperidone (SR)), Ursofiz 300 (Ursodeoxycholic Acid IP 300 mg), Ushield (Sucralfate + Oxetacaine), Esomizole-40 (Esomeprazole 40 mg with Sodium Bicarbonate as buffer), Edoflora (Lyophilized Saccharomyces boulardii 250 mg), Menzovit (Multivitamin, Multimineral, Antioxidants, Iron & Zinc), Finozyme Q10 (Coenzyme Q10 + L-Arginine + Omega-3 fatty acid + Selenium + Lycopene), Esomizole-IT (Esomeprazole (EC) + Itopride (SR)), Ursofiz 450 (Ursodeoxycholic Acid Sustained Release), U Raft (Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate), Rifadoxy 400 (Rifaximin IP 400 mg) and Rifadoxy 550 (Rifaximin IP 550 mg). Names, compositions, images, packaging, and availability may change or differ by market. Verify the exact product and current documents before any regulatory, procurement, or commercial decision.
1. Website content is provided for business and informational purposes only and is not a substitute for professional medical advice, diagnosis, treatment, or approved prescribing information. Patients should consult a qualified healthcare professional.
2. This website does not sell medicines online, display pricing, or accept consumer orders. A listing or inquiry response is not an offer of supply or a guarantee of availability. Terms apply.
3. References to quality, compliance, or external guidelines do not by themselves establish a particular licence, approval, or certification. Evidence applicable to a defined transaction can be requested through the trade inquiry form. See Trade & Quality and Compliance for more information.
Articles on the Healthcare Insights blog follow our content policy. Personal data submitted through inquiry forms is handled as described in the privacy policy.